Aemcolo® (rifamycin SV MMX®)

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals is a publicly traded, revenue-generating biopharmaceutical company with a strategic focus on gastroenterology. Its core expertise lies in the MMX® multi-matrix system, a proprietary technology enabling targeted topical delivery of drugs to the colon. The company's strategy combines the commercialization of its approved products, like Uceris® and Methylene Blue MMX®, with the advancement of its clinical pipeline, including novel candidates for ulcerative colitis and Crohn's disease, while also engaging in strategic licensing and partnership agreements.

Therapeutic Areas

Other Travelers' diarrhea Drugs